Diffusion Pharmaceuticals Inc. (DFFN) financial statements (2023 and earlier)

Company profile

Business Address 300 EAST MAIN STREET
CHARLOTTESVILLE, VA 22902
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments37,31418,51614,1777,9918,8961,55312,006
Cash and cash equivalents37,31418,51614,1777,9918,8961,55312,006
Other undisclosed current assets51026147292377051169
Total current assets:37,82418,77614,6508,9149,6661,60412,175
Noncurrent Assets
Operating lease, right-of-use asset 149247
Property, plant and equipment 1492523504618058
Long-term investments and receivables      250
Long-term investments      250
Intangible assets, net (including goodwill) 8,6398,6398,63915,56815,5687,435
Goodwill    6,9296,929985
Intangible assets, net (excluding goodwill) 8,6398,6398,6398,6398,6396,450
Other noncurrent assets1616322298450233 
Total noncurrent assets:168,9539,4619,28816,47915,8817,743
TOTAL ASSETS:37,83927,73024,11118,20226,14617,48419,918
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities2,9282,3221,6108042,1412,5581,204
Accounts payable9475461,2511995121,68436
Accrued liabilities1,9801,7763596051,6298741,168
Debt  111 5501,880 
Other undisclosed current liabilities 113     
Total current liabilities:2,9282,4361,7218042,6914,4381,204
Noncurrent Liabilities
Long-term debt and lease obligation 36136  550 
Long-term debt, excluding current maturities     550 
Operating lease, liability 36136
Liabilities, other than long-term debt 4442,1191,7862,2253,311 
Deferred tax liabilities, net1,7862,2243,279 
Deferred income tax liabilities 4442,119
Other liabilities    132 
Other undisclosed noncurrent liabilities      2,275
Total noncurrent liabilities: 4802,2551,7862,2253,8612,275
Total liabilities:2,9282,9153,9762,5904,9168,3003,478
Stockholders' equity
Stockholders' equity attributable to parent34,91124,81420,13415,61221,2309,18516,440
Common stock10264333151019
Additional paid in capital164,815130,660111,82595,53382,77069,364115,532
Accumulated deficit(130,005)(105,909)(91,724)(79,925)(61,555)(60,189)(99,111)
Total stockholders' equity:34,91124,81420,13415,61221,2309,18516,440
TOTAL LIABILITIES AND EQUITY:37,83927,73024,11118,20226,14617,48419,918

Income statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Operating expenses(24,677)(15,975)(11,552)(18,959)(11,348)(18,372)(23,827)
Operating loss:(24,677)(15,975)(11,552)(18,959)(11,348)(18,372)(23,827)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
    (2,870) 6
Interest and debt expense   (3)(100)(30) 
Loss from continuing operations before equity method investments, income taxes:(24,677)(15,975)(11,552)(18,962)(14,319)(18,401)(23,821)
Other undisclosed income from continuing operations before income taxes1371148515511,898  
Loss from continuing operations before income taxes:(24,540)(15,861)(11,466)(18,807)(2,420)(18,401)(23,821)
Income tax expense (benefit)4441,675(333)4371,056365 
Net loss attributable to parent:(24,096)(14,185)(11,799)(18,370)(1,365)(18,037)(23,821)
Preferred stock dividends and other adjustments   (8,254)(1,252)  
Other undisclosed net loss available to common stockholders, basic (1,950)     
Net loss available to common stockholders, basic:(24,096)(16,136)(11,799)(26,624)(2,617)(18,037)(23,821)
Other undisclosed net loss available to common stockholders, diluted    (22,072)  
Net loss available to common stockholders, diluted:(24,096)(16,136)(11,799)(26,624)(24,689)(18,037)(23,821)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss:(24,096)(14,185)(11,799)(18,370)(1,365)(18,037)(23,821)
Comprehensive loss, net of tax, attributable to parent:(24,096)(14,185)(11,799)(18,370)(1,365)(18,037)(23,821)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: